We offer a turn-key medical imaging solution for clinical trials in nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD). Our robust, quantitative biomarkers and artificial intelligence-driven digital pathology services provide standardized insight into patient health.


Liver Fat (MRI-PDFF)

Liver Stiffness (MRE)

Digital Pathology

Clinical research opportunity

Multi-organ characterization for comprehensive assessment of patient health

Expert central reads of quantitative metrics using our platform-based services for:

Liver, kidneys, pancreas, spleen, heart, aorta, biliary tree, colon, body composition, and bone mineral density.

Imaging Technologies include: 

MRI, computerised tomography (CT), positron emission tomography (PET), DXA, endoscopy, and digital pathology.

Standardized and reproducible results

Our biomarkers have excellent reproducibility and repeatability (7) with diagnostic accuracy that is superior to others. This enables more reliable monitoring of disease progression as a response to treatment and allows smaller trials to be run with more confidence. (19,20,21)

Our proprietary technology corrects for iron content, field strength, and manufacturer differences to deliver a “corrected T1” or cT1. This allows more robust metrics to be collected, thereby supporting multi-site trials.